Author

C. Kurhade

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 14

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 14 Research Focus:host-pathogen & immune response· 13 Organism:human· 11 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

P.-Y. Shi· 14 shared X. Xie· 14 shared J. Zou· 11 shared H. Xia· 8 shared P. Ren· 7 shared A. Muik· 4 shared D. Cooper· 4 shared M. Liu· 4 shared

Activity by Year

2021-2023 · peak 11/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

14 shared papersMicrobiology

P.-Y. Shi

Mutual co-authors in cluster

Author profile →

14 papers

Recent·Most cited

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1

Y. Hu, J. Zou, C. Kurhade, X. Deng, H. C. Chang, D. K. Kim, P.-Y. Shi, P. Ren, X. Xie

This study compares the neutralization evasion of SARS-CoV-2 variants BA.2.86, XBB sublineages, and CH.1.1, finding BA.2.86 less evasive than XBB sublineages but CH.1.1 most evasive.

bioRxiv · Sep 10, 2023Microbiology

S:D614G and S:H655Y are gateway mutations that act epistatically to promote SARS-CoV-2 variant fitness

L. Yurkovetskiy, S. Egri, C. Kurhade, M. A. Diaz-Salinas, J. A. Jaimes, T. Nyalile, X. Xie, M. C. Choudhary, A. Dauphin, J. Z. Li, J. B. Munro, P.-Y. Shi, K. Shen, J. Luban

This study shows that S:D614G and S:H655Y mutations enhance SARS-CoV-2 infectivity by stabilizing the Spike protein in an open RBD conformation, acting epistatically with the polybasic S1/S2 cleavage site.

bioRxiv · Mar 30, 2023 · PreprintMicrobiology

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

J. Zou, C. Kurhade, S. Patel, N. Kitchin, K. Tompkins, M. Cutler, D. Cooper, Q. Yang, H. Cai, A. Muik, Y. Zhang, D.-Y. Lee, U. Sahin, A. S. Anderson, W. C. Gruber, , P.-Y. Shi

This study compares the neutralizing antibody responses induced by monovalent and bivalent BA.4/5 vaccines against multiple Omicron sublineages in individuals over 55 years old, finding the bivalent vaccine elicits stronger neutralization.

bioRxiv · Nov 17, 2022 · PreprintMicrobiology

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages

H. Xia, J. Yeung, B. Kalveram, C. J. Bills, J. Y.-C. Chen, C. Kurhade, j. Zou, S. G. Widen, B. R. Mann, R. J. Kondor, T. C. Davis, B. Zhou, D. E. Wentworth, X. Xie, P.-Y. Shi

This study examines the replication and cross-neutralization of SARS-CoV-2 Omicron sublineages in mice and human airway cultures, finding distinct antigenic profiles and bivalent vaccine support.

bioRxiv · Nov 8, 2022Microbiology

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster

C. Kurhade, J. Zou, H. Xia, M. Liu, H. C. Chang, P. Ren, X. Xie, P.-Y. Shi

This study evaluates the neutralization effectiveness of parental mRNA vaccines and BA.5-bivalent boosters against new SARS-CoV-2 variants, showing limited neutralization against BA.2.75.2, BQ.1.1, and XBB.1.

bioRxiv · Oct 31, 2022Microbiology

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants

P. Qu, J. P. Evans, C. Kurhade, C. Zeng, Y.-M. Zheng, K. Xu, P.-Y. Shi, X. Xie, S.-L. Liu

This study identifies mutations in the Omicron subvariant spike protein that reduce fusogenicity and increase endosomal entry, revealing mechanisms behind their immune evasion and pathogenesis.

bioRxiv · Oct 15, 2022 · PreprintMicrobiology

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine

X. Xie, J. Zou, C. Kurhade, M. Liu, P. Ren, P.-Y. Shi

This study evaluates the neutralization of SARS-CoV-2 Omicron sublineages by different vaccination regimens and finds that 4-dose mRNA vaccines provide lower neutralization compared to 2-dose plus BA.1 infection.

bioRxiv · Jul 29, 2022 · PreprintMicrobiology

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection

C. Kurhade, j. Zou, H. Xia, M. Liu, Q. Yang, M. Cutler, D. Cooper, A. Muik, U. Sahin, K. U. Jansen, P. Ren, X. Xie, K. A. Swanson, P.-Y. Shi

This study evaluates the neutralization of Omicron sublineages and Deltacron by BNT162b2 vaccine or BA.1 infection, finding BA.4/5 shows highest evasion.

bioRxiv · Jun 5, 2022Microbiology

Cross neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

J. Zou, C. Kurhade, H. Xia, M. Liu, X. Xie, P. Ren, P.-Y. Shi

The paper assesses cross-neutralization of Omicron BA.1 sera against BA.2, BA.3, and a pre-Omicron strain, finding reduced neutralizing titers against heterologous variants.

bioRxiv · Mar 30, 2022Microbiology

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

C. Kurhade, j. Zou, H. Xia, H. Cai, Q. Yang, M. W. Cutler, D. Cooper, A. Muik, K. Jansen, X. Xie, K. Swanson, P.-Y. Shi

This study assesses the neutralization of Omicron sublineages BA.1, BA.2, and BA.3 by BNT162b2 vaccine sera, finding reduced neutralization compared to the original SARS-CoV-2 strain.

bioRxiv · Mar 24, 2022Microbiology

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions

Y. Liu, X. Zhang, J. Liu, H. Xia, J. Zou, A. E. Muruato, S. Periasamy, J. A. Plante, N. E. Bopp, C. Kurhade, A. Bukreyev, P. Ren, T. Wang, V. D. Menachery, K. S. Plante, , P.-Y. Shi

This paper describes a live-attenuated SARS-CoV-2 vaccine candidate with deleted ORFs that shows reduced replication and attenuation in animal models, and reports its protective efficacy against wild-type virus challenge.

bioRxiv · Feb 14, 2022Microbiology

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants

J. Pitts, J. Li, J. Perry, V. Du Pont, N. Riola, L. Rodriguez, X. Lu, C. Kurhade, X. Xie, G. Camus, S. Manhas, R. Martin, P.-Y. Shi, T. Cihlar, D. P. Porter, , J. P. Bilello

This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.

bioRxiv · Feb 9, 2022Microbiology

Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine

H. Xia, J. Zou, C. Kurhade, H. Cai, Q. Yang, M. Cutler, D. Cooper, A. Muik, K. U. Jansen, X. Xie, K. A. Swanson, P.-Y. Shi

This study evaluates the neutralization of Omicron SARS-CoV-2 by two or three doses of the BNT162b2 vaccine, showing increased neutralization with three doses but reduced durability over time.

bioRxiv · Jan 21, 2022 · PreprintMicrobiology

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

j. Zou, H. Xia, X. Xie, C. Kurhade, R. R. Machado, S. C. Weaver, P. Ren, P.-Y. Shi

This study assesses cross-neutralization against Omicron SARS-CoV-2 from prior non-Omicron infections and finds significantly lower neutralization titers compared to the original strain.

bioRxiv · Dec 20, 2021Microbiology